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Table 1: Hypothetical Set of Life-Saving Interventions
Program A B C
Cost 800 240 150
Total Lives Saved 32 30 30
Lives Saved I 16 30 0
Lives Saved II 16 0 30
$ Beneﬁt of Lives Saved 640 900 300
Cost per Life Saved 25 8 5
Beneﬁt-Cost Ratio 0.8 3.8 2
Justice and Allocation in International Health Aid 
IS THE ECONOMIC JUSTIFICATION RATIONAL?
PLAMEN NIKOLOV
I
magine you are in charge of creating 
health policies in a small country 
with binding resources. Suppose that 
you have been granted a ﬁxed amount of 
assistance, which may be applied to one 
of two medical programs. Program A, by 
focusing on those at-risk for a disease, will 
spare one million people by preventing 
them from acquiring the disease in the 
future. Program B focuses on those who 
have already contracted the virus and are 
therefore suffering from severe health 
problems. Should most of the funding be 
allocated to Program A, where the effects 
would be greater? Or should they be 
allocated to Program B, since it focuses 
on individuals who currently are severely 
ill? Should the funds be evenly divided? 
Trying to decide on the best resource 
allocation mechanism for international 
health aid will forces one to examine the 
issue from f both efﬁciency and ethical 
perspectives. 
While this may be a hypothetical 
example, many development and health 
practitioners in Africa face a similar trade-
off when allocating limited resources 
between HIV prevention and anti-
retroviral treatment. 
Developed, middle-income, and even 
many low-income countries around 
the world can ﬁnance both prevention 
efforts and anti-retroviral treatment 
for HIV/AIDS, but countries with very 
low incomes face binding resource 
limitations. In these countries, the 
issue is to what extent the international 
community should fund anti-retroviral 
therapy. … [I]f the goal is to maximize 
the health beneﬁts produced, developing-
country governments and international 
institutions should focus their health 
spending ﬁrst on the prevention of 
HIV transmission, before moving on 
to treatment. The opportunity cost of 
emphasizing HIV/AIDS treatment before 
undertaking prevention in a resource-
constrained environment is measured in 
millions of lives needlessly lost.1
Views such as these underline the 
challenges involved in determining what 
constitutes a viable policy for international 
health aid, while neglecting the ethical 
implications of reliance on the primacy 
of the economic cost-effectiveness 
perspective. Given the funding limitations 
for international health projects, when 
should society allocate resources to produce 
“best outcomes” and when should it give 
the severely ill a fair chance to beneﬁt?
Methods
The economic perspective on which the 
above argument is grounded is consistent 
with the views of many economists. 
All scholarship in the social sciences, 
however, cannot help but reﬂect the 
values and biases of its authors or their 
disciplines. Do others ﬁnd this economic 
focus on health beneﬁts maximization 
convincing when human lives are at stake? 
Much of the debate among social 
scientists focuses on three characteristics: 
equity, efﬁciency, and impact. Let us 
consider a hypothetical set of life-saving 
interventions—programs A, B, C. Cost 
effectiveness analysis (CEA) and beneﬁt 
cost analysis (BCA) are two traditional 
economic cost-beneﬁt tools. Cost 
effectiveness is a method that favors 
interventions which minimize cost per 
life saved—Program C in Table 1. Beneﬁt 
cost analysis, on the other hand, selects 
those interventions with the highest dollar 
beneﬁts of lives saved/cost per intervention 
ratio—Program B in Table 1. Both health 
economists and public health practitioners 
employ a system for selecting the policy 
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Table 2: Hypothetical Set of Life-Saving Interventions
Program A B C
Cost 800 240 150
Total DALYs Gained 32 30 30
DALYs Gained I 16 30 0
DALYs Gained II 16 03 0
$ Beneﬁt of DALYs Gained 640 600 600
Cost per DALY Gained 25 85
Beneﬁt-Cost Ratio 0.8 2.5 4
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which produces the most health per dollar 
spent; though some economists prefer to 
maximize social welfare per dollar spent.
Another technical concept, burden 
of disease, has gained momentum in 
measuring a society’s health gap: the gap 
between society’s health under ideal and 
actual conditions. A cost-effectiveness 
analysis may also be conducted in terms 
of disability-adjusted life years (DALY), 
rather than in lives saved, as in Table 1. It 
is important to note, however, that health 
interventions often have meaningful 
non-health ramiﬁcations—increased 
income, savings, school attendance, etc. 
In such cases, cost effectiveness alone is 
insufﬁcient, and BCA must be used. 
This observation creates an important 
question. If beneﬁt of lives is at stake, 
how should it be measured? Perhaps 
more importantly, what are the ethical 
values embedded in the measurement? 
Economists prefer two broad methods 
to assign value: willingness to pay and 
human capital.
Policy Challenges
Valuing human life through only 
an economic lens can entail some 
challenges. During his service as vice 
president and chief economist of the 
World Bank, Lawrence H. Summers 
was dogged by a memo bearing 
his name, purporting to advocate 
exportation of polluting industries to 
poor nations and dumping toxic wastes 
there. The memo, dated December 12, 
1991, found its way to the press, and 
circulated widely on the Internet. In it, 
Summers wrote:
Just between you and me, shouldn’t the 
World Bank be encouraging MORE 
migration of the dirty industries to the 
LDCs? I can think of three reasons: 
(1) the measurements of the costs of 
health impairing pollution depends on 
the foregone earnings from increased 
morbidity and mortality. From this 
point of view a given amount of health 
impairing pollution should be done in 
the country with the lowest cost, which 
will be the country with the lowest 
wages.2 … I think the economic logic 
behind dumping a load of toxic waste in 
the lowest wage country is impeccable 
and we should face up to that.
Many international development 
practitioners sympathized with the 
following response offered by Brazil’s 
then-Secretary of Environment, Jose 
Lutzenburger:
Your reasoning is perfectly logical but 
totally insane... Your thoughts [provide] 
a concrete example of the unbelievable 
alienation, reductionist thinking, social 
ruthlessness and the arrogant ignorance of 
many conventional ‘economists’ concerning 
the nature of the world we live in.
Summers’ memo misses an important 
consideration of how policy is made. It is 
not the economic logic of his argument that 
is at fault—despite requiring a few strong 
assumptions but rather that Summers tries 
to give a static interpretation to a dynamic 
process. The economic perspective is just 
one tool in the dynamic policy-making kit. 
A policy is by deﬁnition a political process, 
an equilibrium produced by the assorted 
ethical valuations of numerous policy 
stakeholders. 
A policy stakeholder like Summers—
relying on assumptions about best aggregate 
outcomes only and without distributional 
considerations—is likely to assume too 
much about the other stakeholders in 
the policy process. Either he incorrectly 
assumes common rationality for all policy 
stakeholders or he faces uncertainty 
regarding the ethical valuations of those 
stakeholders who favor fair chances in the 
HIV debate, or who see the policy debate 
as both health problem and development 
issue. The ability to understand various 
perspectives and account for them in the 
policy proposal process is a trademark of an 
effective leader.
International Health Aid
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Although there is no single theoretical 
basis for CEA, BCA, and related 
techniques, utilitarian considerations have 
been an important factor in the ethical 
analysis and justiﬁcation of such practices.
Following Jeremy Bentham, John 
Stuart Mill proposed an intuitively 
straightforward standard to decide 
whether actions were right or wrong. 
According to Mill, actions are right in 
proportion as they tend to promote 
happiness, and wrong as they tend 
to produce unhappiness, pain, and 
the privation of pleasure. Because 
utilitarians believe that both happiness 
and unhappiness can be measured in 
discrete units, this theory is particularly 
well-suited to a mathematical analysis 
in which the ‘utility’ of any given action 
can be determined by subtracting the 
pain it causes from the happiness is 
brings about. The goal of moral conduct 
is the production of the greatest social 
happiness or social welfare utility.
Health interventions chosen to 
minimize the disease burden will 
inevitably lead to ethical challenges. For 
example, many multilateral organizations, 
such as the World Bank, analyze cost-
effectiveness in terms of DALYs. This 
tool, however, assigns value differently 
to individuals of different ages; DALYs 
for infants and the elderly are given 
less weight than adolescents and those 
of working age. DALYs also place less 
weight on the lives of the disabled. This 
type of analysis places policy makers in 
a complicated position, where they may 
feel as if they must chose between cost-
effective outcomes and equitable, ethical 
treatment.
This type of priority saving creates 
a major ethical dilemma between best 
outcomes versus fair chances with 
respect to age and disability/illness 
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severity. Utilitarian partialists argue that 
most people—if placed in an “original 
position” in which they were unaware 
of their future economic and social 
circumstances—would elect to have 
resources distributed according to a 
utilitarian calculus, thereby maximizing 
the average utility over the whole of 
society, hence their own expected utility. 
In contrast to this utilitarian application 
of the veil of ignorance, which places equal 
value on the preferences—utilities—of 
every member of society, other theorists 
argue that, when placed in the original 
position, rational individuals would seek 
to maximize the prospects of the least 
well-off member of society. According to 
this ‘maximin principle,’ the primary goal 
of any social policy should be to maximize 
the welfare of persons most in need. 
However, many development 
practitioners are dedicated to helping 
the worst off, not to making utilitarian 
calculations. Bioethicists, such as Norman 
Daniels and Paul Menzel, favor the 
use of equity weights in addition to 
consideration of health utility calculus.3,4
They argue that CEA calculations should 
incorporate severity of illness, level of 
health potential, maintenance of hope, 
age, and assurance of treatment. Equity 
weights permit the formalization of “fair 
chances” considerations in the allocation of 
healthcare.
Gender Perspective
While gains have been made, gender 
inequalities in health and education 
are still striking. Two-thirds of the 800 
million people in the world who lack 
basic literacy skills are female. Girls 
are twice as likely as boys to die from 
malnutrition and preventable diseases, 
and half a million women die each year 
from complications during pregnancy, 
ninety-nine percent of whom live in 
developing countries.5 Investments 
in women’s and girls’ education and 
healthcare yield some of the highest 
returns of all development investments, 
including reduced rates of maternal 
mortality, better educated and healthier 
children, and increased household 
incomes.6
Modern cost-effectiveness mechanisms 
do not incorporate broader gender 
equity considerations per se. The striking 
absence of gender inequality from most 
aid-allocation tools suggests it is unlikely 
to be addressed in health treatment—a 
fact that is particularly worrisome due to 
higher prevalence of HIV for females in 
sub-Saharan Africa.7
What is the Best Policy Decision?
Drafting health policy involves making 
tough decisions between best outcomes 
and fair chances. Economic cost-
effectiveness would favor prevention 
efforts coupled with distribution of 
antiretrovirals only to economically 
productive individuals. Such a strategy 
would increase economic prosperity 
and government funds, allow time 
for replacement labor to be trained, 
and reduce the overall impact of the 
pandemic. But it also involves difﬁcult 
ethical decisions for government 
leaders. It is also bound to be politically 
unfeasible given the varying preferences 
of development stakeholders and the 
ethical principles that underlie them. 
Bioethicists, development workers, 
and public health practitioners have 
raised objections to the use of CEA for 
prioritization in the health sector, and 
it has been shown that most people’s 
healthcare priorities diverge from those 
recommended by CEA. 
This is a complex issue, on which 
there are conﬂicting considerations 
and little consensus. Limited surveys 
indicate a sharp difference between 
health professionals, who tend to favor 
the more cost-effective alternative, and 
the general public, who favor giving all 
those in need a chance to obtain the 
necessary treatment or prevention.8 This 
division of opinion goes to the heart of 
the debate over CEA and BCA, creating 
a dilemma for those health professionals 
who maintain that health policy should 
be based on the values of the affected 
population.
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